Tricida, Inc. (TCDA)
(Delayed Data from NSDQ)
$33.51 USD
+1.26 (3.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.51 USD
+1.26 (3.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update
by Zacks Equity Research
Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.
Do Options Traders Know Something About Tricida (TCDA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Tricida (TCDA) stock based on the movements in the options market lately.
Tricida (TCDA) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Tricida (TCDA) has been struggling lately, but the selling pressure may be coming to an end soon
Tricida (TCDA) Plummets on Regulatory Update on Veverimer
by Zacks Equity Research
Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).
Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour
by Zacks Equity Research
Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour
4 Stocks Set to Pop on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
Will Tricida Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Tricida.